Amryt Pharma (AMYT) Receives “Speculative Buy” Rating from Beaufort Securities

Beaufort Securities reiterated their speculative buy rating on shares of Amryt Pharma (LON:AMYT) in a report issued on Tuesday.

Separately, Shore Capital cut their price objective on Amryt Pharma from GBX 86 ($1.17) to GBX 70 ($0.95) and set a house stock rating on the stock in a research note on Thursday, September 21st.

Shares of Amryt Pharma (AMYT) opened at GBX 20.15 ($0.27) on Tuesday. Amryt Pharma has a one year low of GBX 16.14 ($0.22) and a one year high of GBX 29.50 ($0.40). The stock has a market capitalization of $55.65 and a P/E ratio of -287.86.

TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2018/01/12/amryt-pharma-amyt-receives-speculative-buy-rating-from-beaufort-securities.html.

Amryt Pharma Company Profile

Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.

What are top analysts saying about Amryt Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amryt Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit